



Next-generation potent painkiller with low side effects

Candidate drug for treating acute and severe chronic pain through opioid receptor conformational modulation

DBPR116: Opioid Receptor Allosteric Modifier

Ueng Shau-Hua, Yeh Shiu-Hwa, Lin Shu-Yu, Shih Chuan, Loh Horace, Chao Yu-Sheng

**National Health Research Institutes
Medical School University of Minnesota**


DBPR116 (a prodrug of BPRMU191) is a unique allosteric modulator of mu-opioid receptor (BPRMU191)

- Project Name** DBPR116 (A prodrug of BPRMU191)
- Target Class** mu-opioid receptor
- Compound Class** antagonist to agonist allosteric modifier (AAM)
- Comparator**



AAM: none

allosteric modifier: BMS986121&BMS986122
(Bristol-Myers Squibb Company)


opioid: Morphine, Buprenorphine, Fentanyl, Methadone
- Market** \$15~20 billion/year
- Therapeutics Area** pain
- Indication** renal colic, acute pancreatitis, angina, chronic neuropathic pain, chronic regional complex pain syndrome, cancer pain




cAMP assay




β-arrestin assay



Endocytosis assay





DBPR116 is a prodrug of BPRMU191



Summary of animal pharmacology

	DBPR116 +1 mg/kg naltrexone	Morphine
ED ₅₀ (mg/kg)	11.9 (mMOR), 2.4 (hMOR)	1.9 (mMOR), 1.1 (hMOR)
AUC (min x sec)	200-600	450-750
Threshold (gram)	0.7-0.9	0.2-0.3
Tolerance	no	no
Threshold (gram)	0.5-0.7	0.2-0.7
Tolerance	no	< 6 days
GI inhibition (%)	+	+++
Decrease in Respiratory frequency (%)	++	+++
Addiction	+	+++

 Acute thermal pain (Tail-Flick test)

 Cancer pain (Von Frey test)

 ddC-induced neuropathic pain (Von Frey test)

The primary advantages and market differentiation of DBPR116

- DBPR116 (a prodrug of BPRMU191) is a novel “First-in-Class” AAM which can combine effectively with MOR antagonist (such as naloxone or naltrexone) and produce impressive anti-nociception effects in multiple pain models (mice)
- DBPR116/naltrexone combination also exhibit better tolerance in cancer pain and efficacy in neuropathic pain models
- AAM/MOR antagonist combination also exhibited significant less adverse effects (compare to morphine) on:
 - ✓ Constipation
 - ✓ Addiction
 - ✓ Tolerance